COPDCompEx: A novel composite endpoint for COPD exacerbations to enable faster clinical development - 12/11/20
Abstract |
Background |
Frequency of moderate and severe chronic obstructive pulmonary disease exacerbations is an important endpoint in clinical trials, but makes them large and lengthy when powered to evaluate it. We aimed to develop a composite endpoint (COPDCompEx) that could predict treatment effect on exacerbations, enabling the design of shorter early phase clinical trials requiring fewer patients.
Methods |
In this post hoc analysis, data from 20 randomized controlled trials were used to develop and test COPDCompEx. Diary events were tested against predefined threshold values for peak expiratory flow, reliever medication use, and symptoms. A COPDCompEx event was defined as first occurrence of a diary event, a moderate or severe exacerbation, or a study dropout. Ratios of event frequency, treatment effect and future trial sample size were compared between COPDCompEx and moderate and severe exacerbations.
Findings |
At 3 months, the proportion of patients experiencing COPDCompEx events increased over 3-fold versus exacerbations alone. All components contributed to COPDCompEx event rate. Treatment effects at 3 months were closely matched between COPDCompEx and exacerbations, and the large net gain in power substantially reduced the required sample size.
Interpretation |
COPDCompEx may be used to predict treatment effect on moderate and severe exacerbations of chronic obstructive pulmonary disease. This may enable the design of shorter Phase 2 clinical trials requiring fewer patients when compared with current exacerbation studies, with exacerbations as a key Phase 3 endpoint. This would, therefore, allow more efficient decision-making with reduced burden and risk to study participants.
Le texte complet de cet article est disponible en PDF.Highlights |
• | COPDCompEx is a novel endpoint to measure treatment effects on COPD exacerbations. |
• | COPDCompEx 3-month treatment effect reflected that on exacerbations at 6–12 months. |
• | All components contributed to the COPDCompEx event rate. |
• | The enhanced power of COPDCompEx may facilitate shorter and smaller clinical trials. |
• | The value of including peak flow suggests its utility as an assessment tool in COPD. |
Keywords : Clinical trial endpoints, Drug development, Exacerbations, Treatment effect
Plan
Vol 173
Article 106175- novembre 2020 Retour au numéro
Article précédent
- Non-invasive ventilation improves exercise tolerance and peripheral vascular function after high-intensity exercise in COPD-HF patients
- Cássia da Luz Goulart, Flávia Rossi Caruso, Adriana S. Garcia de Araújo, Guilherme Peixoto Tinoco Arêas, Sílvia Cristina Garcia de Moura, Aparecida Maria Catai, Renata Gonçalves Mendes, Shane A. Phillips, Ross Arena, Andréa Lúcia Gonçalves da Silva, Audrey Borghi-Silva
- Are there differences in muscular activation to maintain balance between individuals with chronic obstructive pulmonary disease and controls?
- Larissa Araújo de Castro, Andrea Akemi Morita, Walter Sepúlveda-Loyola, Rubens Alexandre da Silva, Fabio Pitta, Eddy Krueger, Vanessa Suziane Probst
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?